Delta-Fly Pharma's Phase I/II Trial of DFP-10917 and Venetoclax Shows Promise in AML

Key Insights

• Delta-Fly Pharma's Phase I/II study combines DFP-10917 with Venetoclax for AML patients previously treated with Venetoclax, showing encouraging initial safety and efficacy data.
• The trial aims to establish a safer alternative to the standard Azacitidine and Venetoclax combination, potentially leading to FDA approval through collaboration.
• Enrollment is progressing smoothly, with the first three patients demonstrating promising results, suggesting further development of the novel therapy.

Delta-Fly Pharma Inc. has announced encouraging initial data from its Phase I/II study evaluating the combination of DFP-10917 and venetoclax in patients with acute myeloid leukemia (AML) who have previously been treated with venetoclax. The study is currently enrolling patients in its Phase I portion, with the first three patients showing promising safety and efficacy results.

The trial is designed to explore a potentially safer alternative to the existing standard combination chemotherapy of azacitidine and venetoclax, which can be challenging for AML patients. Delta-Fly Pharma is pursuing a combination of DFP-10917 with venetoclax with the goal of securing NDA approval from the FDA, possibly through a collaboration with a major global pharmaceutical company.

DFP-10917: A Novel Approach for AML Treatment

DFP-10917 represents an innovative approach to treating AML, particularly in patients who have relapsed or are refractory to existing treatments. The company is also planning a Phase III study of DFP-10917 in relapsed/refractory AML patients. However, the data cut-off is planned due to the decreasing number of long-term survivors.

Delta-Fly Pharma is committed to developing innovative therapies for cancer patients and is actively seeking collaborations to advance its pipeline. Further inquiries can be directed to Yasundo Yamasaki, Ph.D., Director of Business Development at Delta-Fly Pharma, Inc.